Hemogenyx Pharmaceuticals PLC CDX Antibody Update (2105U)
April 01 2021 - 01:00AM
UK Regulatory
TIDMHEMO
RNS Number : 2105U
Hemogenyx Pharmaceuticals PLC
01 April 2021
1 April 2021
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
CDX Antibody Update
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for blood diseases,
is pleased to issue an update on negotiations regarding the future
development of its leading product candidate CDX bispecific
antibody ("CDX") for the treatment of acute myeloid leukemia
("AML").
On 13 January 2021, the Company announced the completion of
development of CDX with a global pharmaceutical company
("GlobalCo"). With the development phase of the agreement
completed, GlobalCo or the Company may exercise an option to
license the other party's intellectual property necessary to
exploit the CDX antibody on an exclusive worldwide basis.
The Company is pleased to announce that negotiations have
commenced with GlobalCo regarding the form of licensing and further
development of CDX toward clinical trials. The results of these
negotiations and the outline of the path toward the further
development of CDX will be announced upon their completion.
At the same time, the Company is progressing in the development
of its leading product candidate Chimeric Antigen Receptor ("CAR")
T-cells ("HEMO-CAR-T"). As announced on 3 March 2021 , the Company
has engaged a highly experienced consultant in the field of
manufacturing and quality control operations and has initiated the
process of engaging contract manufacturing organizations ("CMOs")
for product development and manufacturing to support Phase I
clinical trials of HEMO-CAR-T. Discussions and negotiations with
CMOs continue and the Directors are confident that the Company is
poised to move ahead toward clinical trials with an outstanding
team, including the University of Pennsylvania, with which the
Company has entered into a Master Translational Research Services
Agreement , the goal of which is to advance HEMO-CAR-T toward
clinical trials.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented:
"We are pleased with the continued interest of GlobalCo in
facilitating the advancement of the CDX antibody toward the clinic,
having concluded the highly successful development phase of this
product candidate. We are also excited about the progress being
made in moving HEMO-CAR-T toward clinical trials. Having two lead
product candidates that have resulted in collaborations with such
esteemed organizations and both moving toward clinical trials is
testament to the Company's exceptional team of scientists and our
dedication to cutting edge science."
About AML
AML, the most common type of acute leukemia in adults, has poor
survival rates (a five-year survival rate of less than 30% in
adults) and is currently treated using chemotherapy, rather than
the potentially more benign and effective form of therapy being
developed by Hemogenyx Pharmaceuticals. The successful development
of the new therapy for AML would have a major impact on treatment
and survival rates for the disease.
About CAR-T Therapy
CAR-T therapy is a treatment in which a patient's own T-cells, a
type of immune cell, are modified to recognize and kill the
patient's cancer cells. The procedure involves: isolating T-cells
from the patient; modifying the isolated T-cells in a laboratory
using a CAR gene construct (which allows the cells to recognize the
patient's cancer); amplifying (growing to large numbers) the newly
modified cells; and re-introducing the cells back into the
patient.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation No 596/2014 until the release of this announcement.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses
as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXDFDLLFEFA
(END) Dow Jones Newswires
April 01, 2021 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Mar 2023 to Mar 2024